Abbott price target lowered to $110 from $123 at Raymond James

Raymond James lowered the firm’s price target on Abbott to $110 from $123 and keeps an Outperform rating on the shares. Abbott’s base business growth accelerated on a y/y basis in Q3, with broad-based revenue strength and base business margin improvement, while management expressed confident in consensus EPS estimates for 2024, the analyst tells investors in a research note.